Neutrophils superoxide anion generation during carvedilol therapy in patients with stable angina.
Neutrophil superoxide anion (O(2)(*-)) generation was measured during carvedilol therapy in patients with stable angina. The carvedilol group comprised 27 patients (18 men and 9 women), aged 38-51 years (mean 47.6 years) with stable angina. Carvedilol was administered in increased every 4-week doses: 12.5, 25 and 50 mg/24 h, respectively. The control group included 12 healthy subjects, aged 39-49 years (mean 45.7 years) with no drug administered. Blood samples were collected from cubital vein before and 4, 8 and 12 weeks after the therapy and once in the control group. Neutrophil O(2)(*-) generation was determined in whole blood without and with opsonized zymosan (OZ) stimulation according to Bellavite et al. method using superoxide dismutase from bovine erythrocytes. O(2)(*-) generation by nonstimulated and OZ-stimulated neutrophils was significantly higher (p<0.05) in patients with stable angina than in the control group. In carvedilol group, statistically significant (p<0.05) decrease in superoxide anion generation by nonstimulated and OZ-stimulated neutrophils was observed 8 and 12 weeks after the therapy and it did not differ from that in healthy subjects. Carvedilol has been shown to inhibit neutrophil O(2)(*-) generation in patients with stable angina.
Kowalski
Jan
J
Department of Internal Medicine and Cardiological Rehabilitation, Medical University of Łódź, Poland.
Błaszczyk
Jan
J
Petecka
Edyta
E
Irzmański
Robert
R
Kowalczyk
Edward
E
Kowalska
Ewa
E
Cegliński
Tomasz
T
Pawlicki
Lucjan
L
D000328:Adult; D000787:Angina Pectoris / Q000188:drug therapy*; D000959:Antihypertensive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002227:Carbazoles / Q000494:pharmacology / Q000627:therapeutic use*; D000077261:Carvedilol; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000187:drug effects*; D011412:Propanolamines / Q000494:pharmacology / Q000627:therapeutic use*; D017382:Reactive Oxygen Species; D013482:Superoxide Dismutase; D013481:Superoxides
D000959:Antihypertensive Agents; D002227:Carbazoles; D011412:Propanolamines; D017382:Reactive Oxygen Species; D000077261:Carvedilol; D013481:Superoxides; D013482:Superoxide Dismutase